Blasko I - Search Results

1

Use of Benzodiazepines in Alzheimer's Disease: A Systematic Review of Literature.

Defrancesco M, Marksteiner J, Fleischhacker WW, Blasko I. Defrancesco M, et al. Among authors: blasko i. Int J Neuropsychopharmacol. 2015 May 19;18(10):pyv055. doi: 10.1093/ijnp/pyv055. Int J Neuropsychopharmacol. 2015. PMID: 25991652 Free PMC article. Review.

2

Abnormalities of amyloid beta precursor protein expression in platelets of patients with Alzheimer disease: do we understand them well enough?

Blasko I, Marx F, Grubeck-Loebenstein B, Marksteiner J. Blasko I, et al. Arch Neurol. 1999 Jul;56(7):889-91. doi: 10.1001/archneur.56.7.889. Arch Neurol. 1999. PMID: 10404994 No abstract available.

3

Efficacy of donepezil treatment in Alzheimer patients with and without subcortical vascular lesions.

Blasko I, Bodner T, Knaus G, Walch T, Monsch A, Hinterhuber H, Marksteiner J. Blasko I, et al. Pharmacology. 2004 Sep;72(1):1-5. doi: 10.1159/000078625. Pharmacology. 2004. PMID: 15292648 Free article.

4

Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias.

Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H, Marksteiner J, Humpel C. Blasko I, et al. Dement Geriatr Cogn Disord. 2006;21(1):9-15. doi: 10.1159/000089137. Epub 2005 Oct 21. Dement Geriatr Cogn Disord. 2006. PMID: 16244482

5

Cognitive deterioration in Alzheimer's disease is accompanied by increase of plasma neopterin.

Blasko I, Knaus G, Weiss E, Kemmler G, Winkler C, Falkensammer G, Griesmacher A, Würzner R, Marksteiner J, Fuchs D. Blasko I, et al. J Psychiatr Res. 2007 Oct;41(8):694-701. doi: 10.1016/j.jpsychires.2006.02.001. Epub 2006 Mar 20. J Psychiatr Res. 2007. PMID: 16542679

6

Analysis of cerebrospinal fluid of Alzheimer patients. Biomarkers and toxic properties.

Marksteiner J, Pirchl M, Ullrich C, Oberbauer H, Blasko I, Lederer W, Hinterhuber H, Humpel C. Marksteiner J, et al. Among authors: blasko i. Pharmacology. 2008;82(3):214-20. doi: 10.1159/000156487. Epub 2008 Sep 23. Pharmacology. 2008. PMID: 18810245

7

Severity of Depression Impacts Imminent Conversion from Mild Cognitive Impairment to Alzheimer's Disease.

Defrancesco M, Marksteiner J, Kemmler G, Fleischhacker WW, Blasko I, Deisenhammer EA. Defrancesco M, et al. Among authors: blasko i. J Alzheimers Dis. 2017;59(4):1439-1448. doi: 10.3233/JAD-161135. J Alzheimers Dis. 2017. PMID: 28731429

8

Bile acid quantification of 20 plasma metabolites identifies lithocholic acid as a putative biomarker in Alzheimer's disease.

Marksteiner J, Blasko I, Kemmler G, Koal T, Humpel C. Marksteiner J, et al. Among authors: blasko i. Metabolomics. 2018;14(1):1. doi: 10.1007/s11306-017-1297-5. Epub 2017 Nov 17. Metabolomics. 2018. PMID: 29249916 Free PMC article.

9

Plasma phosphatidylcholines and vitamin B12/folate levels are possible prognostic biomarkers for progression of Alzheimer's disease.

Blasko I, Defrancesco M, Oberacher H, Loacker L, Kemmler G, Marksteiner J, Humpel C. Blasko I, et al. Exp Gerontol. 2021 May;147:111264. doi: 10.1016/j.exger.2021.111264. Epub 2021 Jan 28. Exp Gerontol. 2021. PMID: 33516907 Free article.

10

Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease.

Blasko I, Grubeck-Loebenstein B. Blasko I, et al. Drugs Aging. 2003;20(2):101-13. doi: 10.2165/00002512-200320020-00002. Drugs Aging. 2003. PMID: 12534311 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42 results

Search Page

Filters